Infection by pathogenic fungi, such as Candida albicans, begins with adhesion to host cells or implanted medical devices followed by biofilm formation. By high-throughput phenotypic screening of small molecules, we identified compounds that inhibit adhesion of C. albicans to polystyrene. Our lead candidate compound also inhibits binding of C. albicans to cultured human epithelial cells, the yeast-to-hyphal morphological transition, induction of the hyphal-specific HWP1 promoter, biofilm formation on silicone elastomers, and pathogenesis in a nematode infection model as well as alters fungal morphology in a mouse mucosal infection assay. We term this compound filastatin based on its strong inhibition of filamentation, and we use chemical genetic experiments to show that it acts downstream of multiple signaling pathways. These studies show that high-throughput functional assays targeting fungal adhesion can provide chemical probes for study of multiple aspects of fungal pathogenesis.
Infection by pathogenic fungi, such as Candida albicans, begins with adhesion to host cells or implanted medical devices followed by biofilm formation. By high-throughput phenotypic screening of small molecules, we identified compounds that inhibit adhesion of C. albicans to polystyrene. Our lead candidate compound also inhibits binding of C. albicans to cultured human epithelial cells, the yeast-to-hyphal morphological transition, induction of the hyphal-specific HWP1 promoter, biofilm formation on silicone elastomers, and pathogenesis in a nematode infection model as well as alters fungal morphology in a mouse mucosal infection assay. We term this compound filastatin based on its strong inhibition of filamentation, and we use chemical genetic experiments to show that it acts downstream of multiple signaling pathways. These studies show that high-throughput functional assays targeting fungal adhesion can provide chemical probes for study of multiple aspects of fungal pathogenesis.
hyphal morphogenesis | small molecule screening | fungal pathogens I n humans, the most widespread fungal pathogen is Candida albicans, which is also one of the most frequent causes of hospital-acquired infections (1, 2) . As an opportunistic pathogen, C. albicans is responsible for common clinical conditions, including oral thrush and vaginitis, but it can also lead to life-threatening systemic infections (candidemia) in immunocompromised patients (3) , resulting in ∼30-50% mortality rates (2) . Furthermore, the estimated annual cost of treating systemic Candida infections exceeds $1 billion per year (1, 2) . A contributing factor to these statistics is the ability of C. albicans to develop resistance to antifungal drugs (4) . For these reasons, new strategies for combating fungal infections without toxicity to humans are a high medical priority.
Adhesion to surfaces is the first step in establishing a fungal infection. Candida cells with a planktonic yeast morphology initiate adhesion, and a subsequent transition from yeast to hyphal morphology leads to tissue invasion and biofilm formation (5) (6) (7) (8) . Biofilm formation is an important step in pathogenesis, because after biofilms form on intravascular devices and catheters, they normally do not respond to conventional treatment and subsequently, can give rise to life-threatening systemic infections (9) . Therefore, biofilm-associated medical devices often have to be surgically replaced (10) .
Here, we report a chemical screen for compounds that prevent adhesion of C. albicans to polystyrene surfaces. One of the identified compounds also inhibited adhesion to human cells. Furthermore, this compound prevented adhesion of other Candida species to polystyrene, diminished the C. albicans yeast-to-hyphal transition, impaired biofilm formation on silicone elastomers, reduced fungal pathogenesis in a nematode infection model, and altered biofilm morphology in a mouse mucosal infection model. Based on its strong inhibition of filamentation, we term this compound filastatin, and we show that it blocks filamentation induced by some but not all external signals. In sum, our chemical screen identified an inhibitor of multiple pathogenesis-related functions that will also be a useful probe of morphological mechanisms as well as a lead for the development of unique antifungal therapeutics.
Results
Identifying Small Molecule Inhibitors of C. albicans Adhesion. To detect small molecules that inhibit C. albicans adhesion, we modified a previous protocol for measuring adhesion of Saccharomyces cerevisiae to polystyrene (11) . We observed that C. albicans cells bind strongly to 96-well polystyrene plates that have been optimized for protein binding (Methods), and we used this robustly bound substrate to set a high threshold for inhibitors of adhesion. Bound cells were stained with crystal violet followed by washing to remove unbound dye and cells. Cells that remained bound after washing were then quantified by measuring dye absorbance. Wells that displayed low A 590 values were confirmed visually (Fig. 1A) .
We screened a library of 30,000 small molecules for compounds that inhibit adhesion of WT clinical isolate C. albicans strain SC5314 (12) . All compounds were dissolved in DMSO, and therefore, we used SC5314 cells exposed only to DMSO as a negative control (Fig. 1A, column 12 ). As a positive control for poor adhesion, we used a C. albicans edt1 −/− strain (13) that lacks a cell wall adhesion protein (Fig. 1A, column 1) . We ranked the normalized scores for each compound (Methods). Of 30,000 compounds, 40 (1.3%) compounds inhibited adhesion by >75%, and many of these compounds fell into two scaffold families [1-benzoyl-4-phenylpiperazines (termed Scaffold 1) and N-phenylbenzamides (termed Scaffold 2)] (Table S1 ). Omitting compounds within this list that were very similar, we reordered 26 of the candidate compounds (termed 1-26) (Table S1 ) for subsequent characterization.
We prioritized the candidate compounds by testing the dose dependence of their effects. Because of the laborious washing required to remove background crystal violet staining, we used an alternative detection reagent, the vital dye alamarBlue. We found that, after two rounds of washing, alamarBlue robustly detected the adhesion differences between the WT SC5314 and edt1 −/− mutant cells ( Fig. 1C and Fig. S1A ). The majority of the reordered compounds were effective at reducing Candida adhesion at 50 μM, which is the concentration originally tested during the screen (Methods). However, on reducing the concentration to 25 μM, some of these compounds were substantially less effective (Fig. 1B) . However, many candidates were able to inhibit adhesion by >50%, even at concentrations as low as 7.5 μM (Fig. 1C) .
Because alamarBlue measures the metabolic activity of live cells, we confirmed these data with an assay that directly detected cells, regardless of viability or metabolism, by measuring adhesion using a C. albicans strain encoding GFP (13) . Both fluorescence measurements and microscopy ( Fig. 1 D and E) of the GFP-expressing strain confirmed that all of the compounds effective in the alamarBlue-based assay impair C. albicans adhesion to polystyrene. We conclude that our chemical screen detected compounds that block adhesion and yielded consistent results, regardless of the detection method.
In addition to experiments with inert surfaces, we also tested how the candidate compounds would affect C. albicans adherence to human cells by measuring binding of GFP-encoding C. albicans cells to monolayers of human lung epithelial A549 cells, which are an effective substrate for Candida adhesion (14) . We tested each of the reordered compounds and observed that compound 4 was, by far, the strongest inhibitor of adhesion to human epithelial cells, which was shown by both fluorescence quantitation ( Fig. 2A) and microscopy ( Fig. 2B) . We, therefore, prioritized study of this compound (Fig. 2F) , which we termed filastatin based on its inhibition of C. albicans filamentation as described below. We showed that filastatin does not affect the viability of human A549 cells, even at concentrations much larger than those concentrations used in the adhesion assay (e.g., 250 μM) (Fig. 2C) . We conclude that filastatin is not toxic to this human cell line under our assay concentrations, but it is unique among our candidates in that it can impair fungal adhesion to both inert surfaces and cultured human epithelial cells.
We next tested whether filastatin could affect adhesion after cells had already bound polystyrene, because this activity could prove useful in a clinical setting. We compared cells continuously incubated with filastatin for 8 h with cells adhered for 4 h (as in our previous assays) (Fig. 1B) followed by 4 h in the presence of filastatin. We observed that filastatin did, indeed, reduce the amount of bound cells when added after adhesion, although not as efficiently as when the compound and cells are coincubated from the start of the experiment (Fig. 2D) . We conclude that filastatin does display some activity against adhered cells, consistent with potential use against pathogen biofilms.
To test the applicability of filastatin to other fungal pathogens, we examined adhesion by additional pathogenic Candida species (15) . Specifically, we observed that filastatin inhibited polystyrene adhesion by C. dubliniensis and C. tropicalis and to a lesser extent, C. parapsilosis (Fig. 2E) . Filastatin, therefore, inhibits adhesion by multiple pathogenic Candida species. Additionally, filastatin (molecular weight = 360 g/mol) has an IC 50 ∼ 3 μM in the GFPbased adhesion assay (Fig. S1B ), equivalent to a concentration of ∼1.1 μg/ml. This value is similar to or less than the effective concentrations of existing antifungal compounds (16) .
Additionally, data in Figs. S2, S3, and S4 compare the activities of filastatin with other compounds from this study and prior studies (17) . Of all these studies, only filastatin inhibited C. albicans adhesion to human cell monolayers, and therefore, we focused additional studies on this molecule.
Filastatin Inhibits C. albicans Biofilm Formation. Fungal biofilm formation on implanted medical devices is a serious medical problem, because these biofilms can lead to life-threatening systemic infections (18) . An established in vitro assay to study device colonization measures biofilm formation on surgical silicone elastomers (19) . In the presence of DMSO vehicle, we confirmed that WT C. albicans cells efficiently formed biofilms on silicone elastomers; in contrast, edt1 −/− mutant cells did not, resulting in the majority of the cells dispersing throughout the media rather than adhering to the elastomer surface (Fig. 3A) . Visual inspection showed that filastatin, but not compounds 6 or 9, effectively kept the cells dispersed in the media rather than on the elastomer surface (Fig. 3A) . Measurements of the media turbidity and biofilm dry weight (Fig. S5 ) confirmed these assessments. Additionally, we observed that compounds 27, Q1, and Q2 also inhibited biofilm formation in this assay (Fig. S5) . Therefore, filastatin has multiple activities, with inhibition of human cell adhesion unique among our candidate compounds (Tables S1  and S2 ). Visual inspection of cells remaining at the end of adhesion assays suggested that some of the candidate compounds inhibit generation of hyphae. Because the ability to interconvert between yeast and hyphal morphologies is usually correlated with pathogenicity (5, 7, 8) , we explored this finding in more detail, examining induction of hyphae on carbon starvation (Spider media) (20) . We used a strain that contains the Red Fluorescent Protein ORF driven by the hyphal-specific HWP1 promoter (21), which provides a molecular reporter for hyphae formation in addition to cell morphology. We observed that filastatin as well as a subset of the other compounds ( Fig. S6A and Table S1 ) blocked formation of hyphae. Together, our data indicate that the related compound pairs (filastatin/27 and Q1/Q2) were effective inhibitors of both hyphal morphogenesis and biofilm formation on silicone elastomers (Fig. 3A and Figs. S5 and S6) . Therefore, the shared backbone of these compounds correlates with inhibition of multiple activities (summarized in Table S2 ).
On titration, we observed that filastatin is effective at inhibiting hyphae formation at concentrations > 2.5 μM (Fig. S6B) , similar to the results observed in the polystyrene adhesion assay (Fig. S1 ). Using this protein reporter assay, the effect of filastatin could be detected within 2 h of Spider media addition (Fig. S6C) . Also, because filastatin blocked filamentation, even after 16 h of incubation (Fig. S6A) , it seemed unlikely that this inhibitory function relied on a reduced growth rate. Although filastatin did modestly reduce growth rates of yeast-form cells in rich media (Fig. S7A) , this effect was less pronounced during hyphal induction, where we assessed growth by both OD and metabolic activity ( Fig. S7 B and C) . Furthermore, filastatin maintained the yeast morphology of cells throughout an 8-h time course (Fig.  S7D) . We conclude that filastatin is a long-lasting inhibitor of C. albicans filamentation.
Hyphal morphogenesis is induced by multiple stimuli that act through multiple signal transduction pathways (5, 22, 23) (Fig.  4E ) and mediated by a complex transcriptional network (8, 24) . In addition to nutrient-poor Spider media, mammalian serum also induces hyphae (25, 26), and we observed that filastatin inhibited the response to both these stimuli (Fig. 3B) . We detected morphological difference between control and filastatintreated cultures as early as 60 min in 10% (vol/vol) serum and 90 min in Spider media. Additionally, a wrinkled colony morphology -GFP, or untagged SC5314 were added to triplicate wells and incubated at 37°C for 90 min with 1% DMSO or 25 μM indicated compounds in 1% DMSO. Wells were washed extensively to remove unbound fungi, and GFP fluorescence was measured on a plate reader. Mean and SD for three wells are shown. (B) Representative differential interference contrast (DIC) and corresponding GFP fluorescence images from the experiment in A. (C) Human cell toxicity. A549 cells were coincubated with 1% DMSO, 250, 100, or 50 μM filastatin, or 1% NaN 3 for 24 h, and cell viability was then measured using alamarBlue. Mean and SD for three wells are shown. (D) Reversal of adhesion. WT C. albicans SC5314 cells were seeded onto 96-well plates. One-half the samples were incubated continuously in the presence of 1% DMSO or 50 μM filastatin as indicated for 8 h at 37°C (left black bar). One-half of the samples were allowed to adhere for 4 h in the absence of compounds, and then, 1% DMSO or 50 μM filastatin was added followed by additional incubation for 4 h at 37°C (reversal; left striped bar). After incubations, plates were washed two times, and bound cells were detected with alamarBlue. Means and SDs (n = 5 independent experiments, 24 wells measured for each) with P value comparisons are shown (unpaired two-tailed t test). (E) Other Candida species. Adhesion assays are the same as in Fig. 1B , with 25 μM filastatin tested for C. dubliniensis and C. tropicalis and 50 μM filastatin tested for C. parapsilosis. Mean and SD for 16 wells are shown. (F) Structure of filastatin. is displayed by C. albicans when grown on solid Spider media, reflecting transitions between hyphal and yeast forms (5, 27) . Notably, this wrinkled phenotype was also abolished by filastatin (Fig. 3B ). Together, our data indicate that filastatin inhibits hyphal morphogenesis and colony morphology phenotypes that depend on the hyphal transition.
Filastatin Inhibits Induction of Hyphal Morphogenesis by Multiple but
Not All Signaling Pathways. To explore the mechanism of filastatin action, we tested whether it would alter hyphal induction in hyperfilamentous mutants. For example, hyphal induction by Spider media requires the cAMP-PKA pathway (23, 26) (Fig.  4E ). Cells constitutively overexpressing the G protein-coupled receptor Gpr1 become hyperfilamentous on solid Spider media by PKA stimulation (26, 28), and we observed that filastatin blocked hyphal morphogenesis in these cells (Fig. 4A ). Stimulation of the PKA pathway also drives phosphorylation of transcription factor Efg1, activating Efg1 to increase expression of genes required for hyphal morphogenesis. We confirmed that cells with a hyperactive Ras1 signaling protein (ras1-G13V) (29), an overexpressed, constitutively active G-α subunit that acts upstream of Efg1 (gpa2-Q355L) (28), or a constitutively expressed Efg1 transcription factor with a phosphomimetic mutation that simulates constitutive PKA signaling (PCKpr-efg1-T206E) (30), indeed, were all hyperfilamentous compared with WT cells in Spider media (Fig. 4B ). However, in the presence of filastatin, cells from all these mutant strains retained a planktonic, budded morphology ( Fig. 4A ). Together, these data suggest that filastatin acts downstream of transcription factor Efg1 ( Fig. 4E ). However, other experiments suggested that filastatin affects more than one signaling pathway. For example, the modified sugar GlcNac also stimulates hyphal morphogenesis but does so independently of the cAMP-PKA pathway; instead, it activates the transcription factor Cph1 (26). On testing morphogenesis driven by GlcNac-containing media or constitutive overexpression of Cph1, we found that filastatin also inhibits formation of hyphae in these cases (Fig. 4C ). These data indicated that filastatin may affect multiple signaling pathways or could act by destroying the ability of the cell to form elongated structures, regardless of the inducing signal.
In addition to nutrient-mediated signals, genotoxic stress promotes hyphal morphogenesis in C. albicans, and the DNA damage signaling kinase Rad53 is required for the hyphal transition (31). In contrast to the above studies, cells treated with the DNA replication inhibitor hydroxyurea (HU) form hyphae, regardless of the presence of filastatin (Fig. 4D) . Together, these data suggest that filastatin is not incompatible with hyphal morphogenesis per se but blocks multiple signaling mechanisms that promote it (Fig. 4E ).
Filastatin Exhibits Antifungal Activity in a Nematode Model of
Infection. In addition to our in vitro assays, we tested whether filastatin affects fungal infections in vivo. We used the previously described deformed anal region (Dar) tail-swelling phenotype (16, 32) as a biomarker to monitor fungal infections in nematode hosts. A small quantity of C. albicans was introduced with the nematode's standard diet of Escherichia coli OP50 cells, and E. coli growth was attenuated with the antibiotic streptomycin to avoid interactions with C. albicans (33). Here, we used a dose of C. albicans that caused all untreated worms to display Dar disease (Fig. 5A ). In contrast, ∼30% of worms treated with either 12.5 μM filastatin or fluconazole during this experiment maintained a healthy phenotype and did not display Dar disease. Worms treated with the same concentration of amphotericin B displayed an even larger decrease in Dar disease, perhaps due to amphotericin B being a fungicidal drug, while fluconazole is fungistatic (34). In any case, these data indicate that filastatin can ameliorate a fungal pathogenesis phenotype in vivo.
We next tested whether filastatin protects Caenorhabditis elegans against killing by C. albicans. C. elegans was exposed to C. albicans in the presence of DMSO, fluconazole, or filastatin. The C. albicans infections greatly shortened the lifespan of the C. elegans hosts compared with uninfected controls (Fig. 5B) . We observed that both fluconazole and filastatin increased the lifespan of the infected worms ( Fig. 5 B and C) , indicating that both these compounds are protective during infection of a live animal. Increased lifespan in the presence of filastatin was statistically significant as confirmed by Kaplan-Meier statistical analysis (P value < 0.012 or less for all three experiments). Therefore, consistent with its in vitro activities, filastatin functions as an antifungal agent in this model infection system.
Filastatin Alters Biofilm Morphology in a Mouse Model of Vulvovaginal
Candidiasis. As an initial test of filastatin in a mammalian infection model, we examined a mouse model of vulvovaginal candidiasis (VVC). This system is ideal for evaluating our compounds, because VVC infections depend on fungal morphogenesis and biofilm formation (35). This assay is medically important, because VVC affects 75% of all women at least once in their lifetimes, and because C. albicans is responsible for 85-95% of these infections (36).
In this assay, excised murine vaginal mucosal tissue is tested as a substrate for infection by Candida cells. This protocol provides a rapid and simple method for optimizing treatment conditions before in vivo infection assays, although it does not measure adhesion to the tissue, because the tissue is not washed before processing for microscopy. One readout in this assay is a measure of the number of viable fungal cells expressed as cfu. We did not observe significant differences between the cfu recovered from untreated and filastatin-treated samples, although because unadhered cells were not washed away, direct comparison with the in vitro adhesion assays cannot be made. Also, in the presence of filastatin, the Candida cells still formed a carbohydrate-rich ECM, which was detected by Con A staining and confocal microscopy (Fig. S8) . However, filastatin modulated the morphology of the C. albicans biofilm during ex vivo VVC, which was revealed by scanning EM (Fig. 5D) , with a predominance of individual yeast-form cells appearing. Therefore, filastatin restrained formation of hyphae in this infection model, consistent with its hyphal inhibition activity in vitro (Figs. 3 and 4) . Future experiments will be required to determine how filastatin affects ultrastructural aspects of biofilm formation and how it may affect adhesion during biofilm formation on mammalian cells.
Discussion
In recent years, the rate at which new drugs are brought to market has slowed (37). Traditional drug discovery methods have often relied on rational drug design, where agents that inhibit a particular protein are selected. However, this approach is time-consuming and can miss important but unanticipated targets. Here, we describe an alternate function-based approach that relies on phenotypic screening without bias to a particular target. To our knowledge, there has not, to date, been a published screen that directly targets fungal adhesion. By targeting adhesion, our screen required removal of unbound cells. Although laborious in a high-throughput setting, this extra effort allowed us to detect a class of compounds that has unique properties. Importantly, because our assays involve intact cells, we avoided the complication of compounds unable to cross the cell wall and/or membranes.
Here, we report discovery of filastatin, which displays multiple activities related to fungal pathogenesis. Filastatin inhibits fungal adhesion to polystyrene and human cells ( Figs. 1 and 2 ), hyphal morphogenesis and colony morphology (Figs. 3 and 4), biofilm formation (Fig. 3) , pathogenesis in a worm infection model (Fig.  5C ), and biofilm morphology on mouse tissue explants (Fig. 5D) . Notably, inhibition of hyphal morphogenesis occurs in liquid culture in the absence of adhesion, suggesting that filastatin affects multiple cellular processes. The effects on morphology were not selected in our primary screen, showing the need for multiple assays to characterize our candidate compounds fully.
We find that small changes in the compounds can lead to different combinations of activities. This observation was most pronounced in the comparison of filastatin with compound 27, which differ by the substitution of a methyl group for a chlorine substitution on one aryl ring ( Fig. S3 and Table S1 ). Filastatin, but not compound 27, effectively inhibited human cell binding, but these two compounds shared the ability to inhibit polystyrene binding, hyphae formation, and biofilm formation (Table S1) . As another example, the quinoline ring-containing compounds Q1 and Q2 do not inhibit polystyrene binding or human cell binding, but they do inhibit hyphae formation and biofilm formation. Conversely, filastatin is not synergistically toxic to fluconazoleresistant cells like Q1 and Q2 (Fig. S4) . More systematic structureactivity relationship studies are underway to better understand the complex pharmacophore of filastatin and explore its molecular target(s). We note that the multiple activities of filastatin leave open the possibility that multiple targets exist.
Several previous experiments suggest a strong link between hyphal morphogenesis and fungal pathogenesis, including tissueassociated biofilm formation. For example, experiments with a doxycycline-inducible transcription factor (NRG1) that governs hyphae formation have shown that the ability to form hyphae is continually required for the lethality associated with systemic candidaisis (6) . Likewise, many mutants defective in hyphae formation are nonpathogenic (7) and poor at biofilm formation, although this correlation is not absolute (38).
Our data show that filastatin blocks the transcriptional induction of the HWP1 promoter (Fig. S6) , which is an early and essential event in the process of hyphal development (23). Notably, filastatin blocks hyphal formation induced by serum, Spider media, and GlcNac but not the genotoxic stress agent HU (Fig. 4) . These data indicate that the structural machinery required for cell elongation and hyphae formation is able to function in the presence of the compound. Therefore, our screen has provided a powerful chemical probe of the signaling mechanisms that govern hyphal formation. Biochemical and molecular genetics experiments are underway to better understand how filastatin affects hyphal development and fungal adhesion.
Methods
During the screen for small molecule adhesion inhibitors, one 5-mL culture of SC5314 cells and two 5-mL cultures of edt1 −/− cells were inoculated with single colonies in yeast nitrogen broth without amino acids supplemented with 30 μg/mL L-leucine, 20 μg/mL L-histidine, 20 μg/mL L-tryptophan, and 25 μg/mL uridine (Supplemented YNB) + 0.15% glucose media and grown overnight with shaking at 200 rpm at 30°C. The next day, these starter cultures were used to inoculate 100-mL cultures for each strain grown under the same conditions. One day later, OD at 600 nm was measured for both cultures. Cells were pelleted at 3,000 × g and resuspended in fresh Supplemented YNB + 0.15% glucose media to a final concentration of 0.5 OD/mL; 200 μL/well 0.5 OD/mL edt1 −/− cells were added to the first column of each 96-well Immulon 2HB flat-bottom microtiter plate (Part No. 3455; Thermo Scientific), and 200 μL/well 0.5 OD/mL SC5314 cells were added to the remaining columns. Cell plating was followed by robotic addition of 2 μL DMSO vehicle to columns 1 and 12; compounds from the University of Massachusetts Medical School Small Molecule Facility DIVERset Library (Chembridge) at a stock concentration of 5 mM were added to columns 2-11 (Fig. 1A) . The wells were mixed by robotic pipetting three times, yielding a final compound concentration of 50 μM. The plates were covered with foil and incubated at 37°C for 4 h. The contents of the wells were then decanted, and 50 μL 0.5% crystal violet (Sigma) in water were added to each well. The plates were covered again and incubated at room temperature for 45 min. The dye was removed by decanting, and the plates were gently rinsed by 10 rounds of submersion in an ice bucket filled with distilled water followed by decanting the water. The water in the bucket was changed after the fifth wash. The plates were then gently inverted onto a paper towel to remove excess water; 200 μL 75% methanol were then added to each well. The plates were incubated for 30 min at room temperature, and then, absorbance at 590 nm was measured. Additional methods are in SI Methods. cells that lack an adhesion protein (2), or their respective GFPexpressing derivatives (2) . Other fungi analyzed included C. tropicalis (a gift from A. B. Onderdonk, Harvard Medical School, Boston), C. dubliniensis (3), and C. parapsilosis strain CDC317 (4). These cells were grown in 6.7 g/L yeast nitrogen broth without amino acids (YNB) supplemented with 30 μg/mL L-leucine, 20 μg/mL L-histidine, 20 μg/mL L-tryptophan, and 25 μg/mL uridine (Supplemented YNB), with 2% glucose added except where indicated otherwise. The SGH284 strain (a gift from Aaron Mitchell, Carnegie Mellon University, Pittsburgh) was used as a hyphal reporter strain; this strain contains the red fluorescent protein (RFP) gene under the control of the endogenous, hyphal-specific HWP1 promoter (5). This strain was grown in Supplemented YNB + 2% glucose that was additionally supplemented with 20 μg/mL L-arginine. C. albicans strains taken in the 1990s from HIV-infected patients enrolled in a prospective clinical study at the University of Texas Health Science Center at San Antonio were obtained from Ted White (Fig. S4) . The strains that we obtained were originally isolated from anonymous patient 59 as described (6, 7).
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The C. albicans strains used for the chemical genetic experiments were gifts from Douglas Johnson (University of Vermont, VT) (8) The Caenorhabditis elegans WT strain N2 was grown at 20°C on nematode growth agar medium (NGM) spotted with Escherichia coli OP50 and maintained as described previously (9) . E. coli OP50 was grown overnight in Luria broth at 37°C.
Chemical Screen Data Analysis. Because of plate-to-plate variability in the magnitude of the signal for the DMSO control wells, we normalized the data. For each plate, the mean A 590 value from column 1 was set to 0.0, and the mean A 590 value from column 12 was set to 1.0, with each experimental well value normalized to these controls. Normalized values from the entire screen were then ranked. Forty compounds yielded a normalized value <0.25 (that is, >75% inhibition of adhesion). Many of these compounds fell into two structural subclasses that we termed Scaffolds 1 and 2 (Table S1 ). We reordered 26 of these compounds (Chembridge) for additional characterization, omitting highly similar ones. Compounds 27, Q1, and Q2 were also obtained from Chembridge. Statistical analyses were carried out using Graphpad Prism5.
alamarBlue-Based Adhesion Assay. Overnight cultures of SC5314 and edt1 −/− cells were grown and plated onto Immulon 2HB 96-well microtiter plates and treated with small molecules as described above. After incubations, media were decanted, and plates were washed two times with 100 μL/well PBS. alamarBlue (Life Technologies) was resuspended to a final concentration of 5% in RPMI buffered with 0.165 M Mops (pH 7.0), and then, 100 μL were added to each well followed by additional incubation for 2 h at 37°C. Fluorescence signals at 555 Ex / 585 Em were read using a SpectraMax M5 Plate reader (Molecular Devices).
For Candida species other than C. albicans, the standard alamarBlue-based adhesion assay conditions were followed, except for C. tropicalis, which adhered less well and therefore, was subjected to a single wash after coincubation with drugs (Fig. 2E) .
GFP-Based Polystyrene Adhesion Assay. SC5314-GFP and edt1 −/− -GFP strains were pregrown overnight in Supplemented YNB + 2% glucose media at 30°C, diluted into fresh Supplemented YNB + 2% glucose media to a final concentration of 5 × 10 6 cells/mL (equivalent to 0.5 OD 600 /mL), and plated onto Immulon 2HB 96-well plates, with each well receiving 0.1 OD of cells. DMSO or compounds resuspended in DMSO were added to the desired final concentration (1% vol/vol DMSO was maintained). Plates were then incubated for 4 h at 37°C. Media were decanted, and plates were washed three times with PBS using a MicroFill microplate dispenser (BioTek), with each well receiving 100 μL PBS. Fluorescence was measured using a Synergy HT plate reader (BioTek) after the addition of 100 μL PBS/ well. For each experiment, untagged SC5314 was analyzed simultaneously to determine background fluorescence that was subtracted from the signal from each well. DIC and fluorescence images were acquired using a Axiovert 200 microscope (Zeiss) equipped with a QICAM FAST cooled mono 12-bit digital camera (Qimaging). Image acquisition was carried out using Openlab imaging software (PerkinElmer).
Epithelial Cell Binding Assay. Human lung epithelial A549 cells (10) were grown to confluence on Nunc 48 well plates in RPMI + 10% FBS and Penicillin/Streptomycin. Media were decanted, and plates were carefully washed three times with PBS to remove unbound cells. Pregrown overnight cultures of SC5314-GFP and edt1 −/− -GFP C. albicans cells were resuspended in fresh Supplemented YNB + 2% glucose at 0.5 OD/mL, and 250 μL yeast suspension were plated onto to each well. After incubation at 37°C for 1.5 h, media were decanted, and the monolayers were washed carefully three times with 250 μL PBS. Fluorescence from bound yeast was measured (485 Ex /535 Em ) using the Synergy HT plate reader (BioTek) after the addition of 100 μL PBS/well. DIC and fluorescence images were acquired as described above for the GFP-based adhesion assay.
Adhesion Reversal Assay. SC5314 cells were pregrown overnight in Supplemented YNB + 2% glucose and resuspended in fresh Supplemented YNB + 2% glucose to a final concentration of 1 OD 600 /mL. Cells were then seeded into Immulon 2HB 96-well plates at 0.1 OD (100 μL) per well. One-half of the samples remained untreated at this point (to test for subsequent reversion test), and one-half received either 50 μM filastatin or 1% DMSO (measuring the effect of continuous exposure to compound). Plates were then incubated for 4 h at 37°C. After this incubation, an additional 100 μL/well Supplemented YNB + 2% glucose were added, bringing final concentrations to 50 μM filastatin or 1% DMSO. Plates were then returned to the 37°C incubator for an additional 4 h. At the end of 8 h of incubation, all media were decanted, and the plate was washed two times with 100 μL/well PBS. This washing was followed by the addition of 100 μL/well 5% alamarBlue in RPMI buffered with 0.165 M Mops (pH 7.0) and additional incubation for 2 h at 37°C. Fluorescence signals at 555 Ex /585 Em were read using a SpectraMax M5 Plate reader (Molecular Devices).
Filamentation Assays. HWP1-RFP reporter. Overnight cultures of SGH584 were pregrown in Supplemented YNB + 2% glucose + arginine media at 30°C to an OD 600 > 13, diluted 1:10 into prewarmed Spider medium [1% Peptone (Difco), 1% Mannitol (Sigma), and 0.2% K 2 HPO 4 (Sigma)] (11) in glass tubes, and grown for 16 h at 37°C shaking at 200 rpm in the presence or absence of drugs as indicated. DIC and fluorescence images were acquired using a Zeiss Axioplan 2 microscope equipped with an Orca ERG 1394 digital camera (Hamamatsu). Image acquisition was carried out using AxioVision 3 imaging software (Zeiss). Chemical genetics. Overnight cultures were grown at 30°C in Supplemented YNB + 2% glucose. The next day, cells were resuspended to 0.1 OD 600 /mL in fresh Supplemented YNB + 2% glucose and grown at 30°C to a density of 0.4 OD 600 /mL. Cells were pelleted and resuspended in Spider medium supplemented with either 1% DMSO alone or 1% DMSO plus 50 μM filastatin and incubated at 37°C for 4 h. Cells were stained with 1 μg/mL Calcofluor white for 15 min and vortexed thoroughly to disperse cells. DIC and fluorescent images of cells were obtained using an EVOS fluorescent microscope (Life Technologies) using a 20× objective. Spider and serum liquid media (Fig. 3B) . SC5314 cells were grown overnight at 30°C in Supplemented YNB + 2% glucose to 13 OD 600 /mL. Cells were diluted 1:10 into either Spider media or Supplemented YNB + 2% glucose + 10% bovine serum as indicated and grown at 37°C for the indicated period. Cells were photographed with DIC optics on an EVOS microscope using a 10× objective. GlcNAc media. SC5314 cells were grown overnight in Supplemented YNB + 2% glucose to 13 OD 600 /mL. Cells were diluted 1:10 into GlcNAc media (0.5% GlcNAc, 0.5% peptone, 0.3% KH 2 PO 4 ) (8) and grown at 37°C for 16 h. Calcofluor-stained cells were imaged as above. Solid Spider media for colony morphology assays. Spider media agar plates (25 mL agar/plate) were overlaid with 250 μL 100% DMSO or 5 mM stock of filastatin in DMSO, yielding final concentrations of 1% DMSO with or without 50 μM filastatin. SC5314 or YTC104 (ADHpr-GPR1) cells pregrown overnight in Supplemented YNB media were diluted into Supplemented YNB to a final concentration of 100 cells/mL, and 200 μL were spread onto the plates. Plates were sealed with Saran wrap and incubated at 37°C for the indicated times. Images of colony edges were obtained using the EVOS microscope (10× objective). Fields of colonies were imaged using a Nikon SMZ800 microscope fitted with a Nikon Coolpix digital camera, and single colonies were imaged using a Leica M165 FC stereo microscope at 12.5× magnification. Hydroxyurea-induced filamentation. SC5314 cells were pregrown overnight in YPD at 30°C, diluted into fresh YPD at a concentration of 5 × 10 6 cells/mL, and grown for 2 h at 30°C. Hydroxyurea was then added to a final concentration of 50 mM, and growth was continued at 30°C for 5 h. Calcofluor-stained cells were imaged as for the GlcNac experiment.
Measurement of Toxicity of Filastatin. A549 cells in RPMI + 10% FBS were seeded into 24-well plates at 1 × 10 5 cells/well and grown overnight at 37°C. Media were removed and replaced with fresh media containing indicated concentrations of filastatin or 1% sodium azide followed by incubation for 24 h. Viability was determined with 5% alamarBlue as above.
Biofilm Formation on Silicone Elastomers. We adapted a published method (12) . Autoclaved, preweighed silicone elastomer squares (PR72034-04N; Bentec) were incubated overnight at 37°C with undiluted bovine serum. After washing with PBS, the squares were transferred to 12-well plates and incubated with 0.5 OD/mL SC5314-GFP or edt1 -/− -GFP cells in Spider medium (with or without drugs as indicated) for 90 min at 37°C and shaking at 200 rpm. Squares were washed in PBS and transferred to new 12-well plates containing fresh Spider medium with fresh drugs, and then, they were incubated for 60 h in a 37°C shaker at 200 rpm. The plates were then photographed, the liquid media were collected for A 600 measurements, and the dry weights of the bound biofilms were measured after drying of the silicone squares in a chemical hood.
Growth Rate Measurements in Spider Media. OD. Overnight cultures of SC5314 cells grown in Supplemented YNB + 2% glucose media were diluted into Spider media at a concentration of 0.1 OD/mL and allowed to grow at 37°C in the presence of either 50 μM filastatin or 1% DMSO as a vehicle control. The means and SDs of OD measurements at the indicated times from three biological replicates are shown. Additional 100-μL aliquots taken at indicated times were fixed with 4% paraformaldehyde for 30 min at room temperature. These aliquots were then stained with Calcofluor and analyzed by microscopy as described for the chemical genetics experiments. alamarBlue. Cultures were grown as above. At the indicated times after transfer to Spider media, 100 μL culture were added to an equal volume of 5% alamarBlue in RPMI and incubated at 37°C for 30 min. The resulting fluorescent signals were measured on a BioTek plate reader as described above.
C. elegans Egg Preparation. Three L3/L4 stage larvae of C. elegans strain N2 were transferred to NGM agar plates seeded with E. coli OP50 and grown at 20°C for 4 d. The worms were washed off the plates with M9 buffer, and the collected liquid was centrifuged at 900 × g for 2 min. The supernatants were aspirated, and the pellets were resuspended in 15 mL 1:4 dilution commercial bleach solution (5.25%) containing 0.25 M NaOH to release the eggs. The suspensions were mixed by inversion for 3 min and then centrifuged for 2 min at 2,000 × g. The supernatants were aspirated, and the pellets containing the eggs was washed two times with M9 buffer and resuspended to a final concentration of 5-6 eggs/μL; 20 μL egg prep solution were added to NGM plates seeded with E. coli OP50. The plates were incubated at 20°C for 2.5 d to obtain a large number of young adults.
C. elegans Deformed Anal Region Disease Assays. Deformed anal region disease was monitored as previously described (13, 14) . Briefly, E. coli OP50 and C. albicans SC5314 cells were grown separately overnight at 37°C. Cells were harvested, and E. coli growth was attenuated by addition of 10 μL 50 mg/mL streptomycin; the mixture was spotted onto NGM agar plates. When needed, compounds were added to the mixture to a final concentration of 12.5 μM. Uninfected control plates were spotted with E. coli alone. A suspension of C. elegans eggs was transferred to each plate. Plates were incubated at 20°C, and deformed anal region disease was visually evaluated for the hatched larvae on day 4.
C. elegans Survival Assays. E. coli and C. albicans strains were grown from single colonies overnight at 37°C in LB and 30°C in YPD, respectively. Culture aliquots were centrifuged at full speed for 1 min. The pellets washed two times in sterile water and finally resuspended to a final concentration of 200 mg/mL for E. coli and OD 600 = 3 for C. albicans; 10 μL 50 mg/mL streptomycin solution were mixed with 2.5 μL E. coli, 0.5 μL C. albicans, and 7 μL sterile water. When needed, drugs were added to the mixture to a final concentration of 12.5 μM, and plates lacking C. albicans were used as negative controls (uninfected). The mixtures were spotted on NGM plates and maintained at room temperature overnight; 20 young adults worms were added to each of three plates (n = 60 for each experimental condition), and the plates were incubated at 20°C. Worms were scored daily by gentle prodding with a platinum wire. Dead worms were discarded, whereas live ones were transferred to new seeded plates for growth overnight at room temperature. Worms accidentally killed while transferring or found dead on the edges of the plates were discarded and censored in our analysis. Statistical analysis was performed using SPSS and GraphPad Prism software: survival curves were obtained using the KaplanMeier method, and P values were calculated using the log-rank test that gives equal weight to all time points.
Mouse Mucosal Infection Studies. The protocol for the ex vivo infections was based on published studies (15) . Mice were administered estrogen (1 μg/mL; 100 μL subQ), and vaginae were harvested after 72 h. Before inoculation, C. albicans SC5314 was pretreated with 50 μM filastatin for 1 h. Tissues were either left uninoculated or inoculated with treated or untreated SC5314 (10 6 blastoconidia) and incubated for 24 h. Tissues were bisected, with one-half used for cfu analysis and one-half processed for scanning EM or confocal microscopy (CM) after staining with Calcofluor to detect yeast (blue) and Concavalin A to visualize ECM (red). Scanning EM images were taken at 1,000× magnification, and CM images were taken at 200× magnification. We performed two independent repeats (n = 6 vaginal explants per experiment). Mouse tissues were acquired and analyzed under protocols approved by the institutional review board of Louisiana State University (Protocol 2835).
SI Results
Filastatin (Scaffold 1) and Compound 14 (Scaffold 2) Do Not Synergize for Inhibition of C. albicans Binding to Polystyrene. Many of our initial set of candidate compounds had one of two distinct chemical scaffolds (Fig. S2A and Table S1 ). We tested whether we could detect any synergistic effects on combining members of these two classes. Specifically, we combined doses of compounds that alone had partial effects on adhesion: filastatin (Scaffold 1) and compound 14 (Scaffold 2). Combining these compounds at these concentrations produced additive but not synergistic reductions in adhesion (Fig. S2B) . Therefore, we focused subsequent experiments on single compounds alone.
Filastatin Is Functionally Distinct from Previously Described Compounds
That Affect Candida Drug Resistance. During the course of our studies, results were published from a high-throughput screen for chemosensitizer compounds that do not impair growth of WT C. albicans but synergize with fluconazole to reduce viability of fluconazole-resistant strains (16) . Notably, the best candidate compound identified (termed Q1 in Fig. S3A and Table S1 ) is a piperazinyl quinoline. Q1 has a backbone similar to our filastatin, with the exception of the quinoline group distal to the piperazinyl linker, which is in contrast to the single-ring nitrophenyl group present in filastatin (Fig. S3A) . We, therefore, tested whether the presence of the quinoline group Q1 affected our adhesion assays or affected the activities of the candidate compounds in a variety of assays. We also tested whether different substitutions on the aryl group adjacent to the carbonyl at the other end of the molecules would correlate with activities, comparing compound 27 with filastatin and comparing a compound that we termed Q2 with Q1 (Fig. S3A) .
We tested this set of compounds for effects on C. albicans adhesion to polystyrene. We observed that both filastatin and compound 27 were effective adhesion inhibitors but that neither compound Q1 nor compound Q2 was inhibitory (Fig. S3B) . Therefore, the presence of the quinoline group on compounds Q1 and Q2 correlated with a lack of activity, and the substitutions on the other end of the compounds were less important. Furthermore, these data show that filastatin and Q1 are functionally distinct, despite their similar chemical backbones.
We also compared these compounds in the human cell binding assay. In this case, only filastatin strongly inhibited C. albicans to human A549 cells (Fig. S3C) . Therefore, perturbation of either of the aryl side groups on both sides of the molecule can impair the human cell adhesion inhibition activity of filastatin, further illustrating the distinct properties of this compound.
Finally, we tested whether filastatin would inhibit growth of fluconazole-resistant C. albicans strains in the presence of low levels of fluconazole, because that activity is the activity described for compound Q1 (16) . To measure cell viability rather than adhesion, we performed alamarBlue-based viability measurements without wash steps using fluconazole-resistant C. albicans strains obtained from an AIDS patient who had been treated with fluconazole for oral candidaisis (6, 7) . We confirmed that compound Q1 does, indeed, synergize with fluconazole to inhibit growth of these strains (Fig. S4) . In contrast, filastatin alone did not affect viability of these fluconazole-resistant clinical isolates, and it did not synergize with fluconazole. These data provide another example of how filastatin and Q1 are functionally distinct, despite some similarity in their structures.
Several Compounds Inhibit Hyphal Morphogenesis. Using the HWP1-RFP reporter strain, we initially tested each of the compounds that inhibit adhesion to polystyrene (Fig. 1B) as well as compounds 27, Q1, and Q2 (Fig. S3A ) at a concentration of 12.5 μM. We observed that filastatin and compounds 14, 27, Q1, and Q2 most potently inhibited hyphal formation and induction of RFP (Fig. 3B and Fig. S6) . Therefore, the compounds with a quinoline group can inhibit hyphae formation but not adhesion to polystyrene or human cells (Fig. S3) . In contrast, other Scaffold 1 compounds (Fig. S2 and Table S1 ) (e.g., compounds 1, 6, 25, and 26) did not block hyphal formation as efficiently as did filastatin, 27, Q1, or Q2, suggesting that minor substitutions on this backbone can affect this assay. Additionally, multiple chemical backbones are able to inhibit hyphae formation, because compound 14 has a Scaffold 2 backbone (Table S1 ). To better discriminate the inhibitory compounds, we tested filastatin, 14, and Q1 at lower concentrations. At 10 μM, all three of these completely blocked the hyphae formation induced by Spider media (Fig. 3A and Fig. S6 ). A few hyphae were observed at 5 μM in the presence of compound 14, and hyphae were detectable in the presence of any of the three compounds at 2.5 μM. We conclude that filastatin, 14, and Q1 all potently inhibit hyphal formation, although these compounds behave differently in adhesion assays ( Figs. 1 and 2) . Fig. S1 . Z′-factor measurement and titration of filastatin. (A) Overnight cultures of SC5314 cells were diluted to 0.5 OD/mL in fresh synthetic complete media (SCM) and plated onto an Immulon 2HB 96-well microtiter plate; 48 wells were treated with either 1% DMSO or 25 μM filastatin, and alamarBlue-based adhesion assays were performed as described in Methods. Z′ factor, a metric for the robustness of the assay, was calculated as described (1); this value should be >0.5 for high-throughput screens. Using alamarBlue, we found the Z′ factor routinely to be >0.6. Therefore, our modified protocol would be well-suited to additional high-throughput screens. Mean and SDs of fluorescence measurements of 48 wells are shown. (B) Assay performed like in Fig. 1D using the GFPencoding SC5314 cells in the presence of indicated concentrations of filastatin. Mean and SDs from four replicate well measurements are shown. Scaffold 1 compounds have a 1-benzoyl-4-phenylpiperazine backbone (that is, they are piperazines with a benzoyl group attached to one nitrogen and an aryl group attached to the other nitrogen). Scaffold 2 compounds are N-phenylbenzamides with two substituted aryl groups separated by an amide bond.
